

HealthLinX Limited

HealthLinX secures \$7.2m funding from a New York-based institutional investor

- \$7.23 million convertible note, advanced on a monthly schedule over a period of up to three years
- Will accelerate worldwide roll out of world's most accurate commercially available ovarian cancer diagnostic OvPlex™
- Funding for second larger study for OvPlex™ due to begin late 2009

5th October 2009, Melbourne: HealthLinX Limited (ASX:HTX) has secured a \$7.23 million convertible note at zero interest, advanced over a period of up to three years. The funding is from the US institutional investor SpringTree Special Opportunities Fund, LP ("SpringTree") to advance commercialisation of HealthLinX's OvPlex™ ovarian cancer diagnostic and fund the second multi centre biomarker trial for OvPlex™ that will include clinicians in Australia, Singapore and the United Kingdom. SpringTree is a New York-based investment fund that makes debt and equity investments in small-cap and mid-cap public companies around the world. KTA Capital, LLC, a New York-based registered broker-dealer, acted as the exclusive financial advisor to SpringTree Global Investors, LLC, the manager of SpringTree, in connection with the transaction.


The first tranche of \$230,000 has been advanced in accordance with the agreement, and subsequent tranches of no less than \$60,000 and, subject to HealthLinX's consent, no more than \$200,000, will be advanced monthly.

The note is convertible at conversion prices that are linked to the market price of the HealthLinX shares. This note includes certain minimum conversion price protections for HealthLinX - it can opt to repay in cash, rather than in shares, the amount outstanding at any time if the conversion price at which HealthLinX would otherwise be issuing shares to the investor were to be lower than a specified price. Additionally, the investor has agreed to the 19.99% limitation on its ownership of HealthLinX's shares.

"This funding facility will allow the company to focus on core activity and achieve internal and external milestones, without the need to devote valuable resources to capital raising activities. It is exciting to see that US investment groups are looking at our company as a company that can deliver high returns with first in class technology. It also vindicates the company's ability to deliver value for shareholders through its existing product OvPlex™ and future targets such as prostate cancer diagnostics." said Nick Gatsios, managing director of HealthLinX. "The funding does not prevent us from entering into additional debt or equity transactions, pharma partnerships or M&A transactions. This secures the company's future and puts it in a strong position as we continue to secure and enter into negotiations with distributors for OvPlex™ in foreign jurisdictions."

"With part of the funding the company will finalise all necessary agreements with collaborators in the United Kingdom and Singapore to commence collection of samples that will allow for the completion of the multi centre study in which 1150 samples will be used to determine sensitivity and specificity of the OvPlex™ panel. Furthermore, the company will also be further validating two novel biomarkers HTX005 and HTX010 in the larger trial. Based on preliminary phase 2 biomarker studies, inclusion of these two novel biomarkers suggest that the panel's performance will be increased to greater than 97% diagnostic efficiency which will clearly place HealthLinX and OvPlex™ as the market leader. It is very exciting to see our collaborators enthusiastic about the data that we have generated on these two new biomarkers that clearly will have a positive impact on our product."

For personal use only



HealthLinx Limited

Speaking from New York, SpringTree's Managing Director Jeff Easton said, "We are delighted to extend our support to HealthLinx and impressed by the strength of the prospects for OvPlex™. These products can satisfy significant unmet demand and have strong points of difference. This is our second Australian investment in the ovarian cancer diagnostics and therapeutics area. We are proud to be putting our funds to work for such a worthy cause."

Enquiries

Nick Gatsios (HealthLinx Limited)	+61 3 9208 4200
Rudi Michelson (Monsoon Communications)	+61 3 9620 3333

About HealthLinx Limited (ASX:HTX)

HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are for diseases with high fatality:

- Ovarian cancer diagnostic (OvPlex™) targeting US\$270m pa market
- Prostate cancer targeting US\$350m pa market

A biomarker is a specific biochemical in the body that measures disease or the effects of treatment.

Commercial sales of the OvPlex™ test have begun in Australia and are soon to commence in the UK. HealthLinx is developing new and increasingly accurate next generation diagnostics and will seek license partners to roll out worldwide sales.

www.healthlinx.com.au

About SpringTree Global Investors, LLC

SpringTree Global Investors, LLC is a New York-based asset management company that makes debt and equity investments in public companies around the world with a focus on small-cap and mid-cap companies requiring US\$5- US\$150 million in debt and/or equity. It invests across a broad range of industries and a wide range of geographies and economic environments.

www.springtreegi.com

Press contact: Jeff Easton – jeaston@springtreegi.com

For personal use only